EuroPharma launches Mesoglycan

Supplement provides bioidentical compounds that play a role in structural support and optimal circulation for the blood vessels.

EuroPharma Inc. has launched Mesoglycan—a clinically studied complex of glycosaminoglycans (GAGs) that are utilized by the body as flexible building blocks in the structure of more resilient arteries and veins. The product provides bioidentical compounds that play a role in structural support and optimal circulation for the body’s more than 60,000 miles of blood vessels.

The electronic database of the National Institutes of Health has archived 74 studies specifically including mesoglycan (also called aortic acid) and its role in supporting a wide variety of physiological systems including: eye health as it relates to retinal circulation; leg circulation and reduction in heavy, tired legs; support of healthy skin on the lower extremities (foot and leg); brain circulation, especially as it pertains to clarity of thought and brain function; as well as coronary artery support and overall heart and circulatory health.

“Mesoglycan is one of the single most powerful tools in the natural medicine toolbox for helping the body build and maintain strong blood vessels. Healthy blood vessels promote optimal circulation, which affects every single action required for life. You can’t move or breathe or digest food or even think without healthy circulation, yet many people overlook the importance of blood vessel strength, integrity, and flexibility,” states Terry Lemerond, president and founder of EuroPharma, Inc.

“Mesoglycan is well-known in Europe for its tremendous health benefits,” states Lemerond, “And I think there are literally millions of people in the U.S. that could benefit from this highly effective product as well.”

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish